Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A

NCT06643819 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

324

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: Sacubitril∙Valsartan(dose maintenance)
DRUG: Sacubitril∙Valsartan(dose increasing)
DRUG: Valsartan

Sponsor

Chong Kun Dang Pharmaceutical